FDA label c815c707-88c6-4834-9279-96251cf1bf66
openFDA label record#
This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.
Verified complete openFDA source JSON
- SPL set ID
- 5e4cf15b-bf7b-4b83-863e-e9ef27741a51
- SPL ID
- c815c707-88c6-4834-9279-96251cf1bf66
- Version
- 26
- Effective date
- 2024-03-22
- Source export date
- 2026-11-13
- Source partition
- 9
- Source file
- https://download.open.fda.gov/drug/label/drug-label-0009-of-0014.json.zip
- Source object key
- raw/openfda/drug-label/2026-11-13/48e89e7994339d0e23bed7c09f727a47746d1fbd440ad66960650182851cb8a9/drug-label-0009-of-0014.json.zip
- Source manifest SHA-256
- 8f2b6d063d44586cf97cedcdf1bdf9e261cc88632cc6855424b801bb206208d7
- Import run
- 20261116T150851Z
- Imported at
- 2026-11-16 17:08:36
Harmonized identifier links#
Every typed identifier imported from the complete openFDA harmonization object is paginated here; values are not reduced to a first match.
| Type | Scope | Identifier | Source field |
|---|---|---|---|
| spl id | c815c707-88c6-4834-9279-96251cf1bf66 | id | |
| spl set id | 5e4cf15b-bf7b-4b83-863e-e9ef27741a51 | set_id |
Warnings cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
5 WARNINGS AND PRECAUTIONS • Thrombocytopenia, neutropenia, and anemia: Monitor blood counts and omit and/or reduce dose for hematologic toxicities. ( 2.2 , 5.1 ) • Mucositis: Monitor at least weekly. If ≥ Grade 2 mucositis is observed, omit and/or reduce dose. ( 2.2 , 5.2 ) • Dermatologic reactions: Reactions, including fatal reactions, have occurred and may be progressive and increase in severity with further treatment. Monitor closely, and omit and/or reduce dose or discontinue FOLOTYN. ( 2.2 , 5.3 ) • Tumor lysis syndrome: Anticipate, monitor, and treat promptly. ( 5.4 ) • Hepatic toxicity: Monitor for toxicity. For liver function test abnormalities Grade 3 or greater, omit until recovery then reduce dose or discontinue therapy as required. ( 2.2 , 5.5 ) • Risk of increased toxicity with renal impairment: Patients with moderate to severe renal function impairment may be at greater risk for increased exposure and toxicity. Monitor patients for renal function and systemic toxicity and adjust dosing accordingly. Avoid FOLOTYN use in patients with end stage renal disease including those undergoing dialysis unless the potential benefit justifies the potential risk. ( 2.1 , 2.2 , 5.6 , 6.2 ) • Embryo-Fetal toxicity: Women should avoid becoming pregnant while being treated with FOLOTYN. Inform pregnant women of the potential harm to the fetus. ( 5.7 , 8.1 ) 5.1 Bone Marrow Suppression FOLOTYN can cause bone marrow suppression, manifested by thrombocytopenia, neutropenia, and/or anemia. Monitor complete blood counts and omit and/or reduce the dose based on ANC and platelet count prior to each dose as outlined in Section 2.2 Table 2 . Administer vitamin B 12 and instruct patients to take folic acid to reduce the risk of treatment-related hematological toxicity [ see Dosage and Administration ( 2.1 , 2.2 ) and Adverse Reactions ( 6.1 ) ]. 5.2 Mucositis FOLOTYN can cause mucositis. Monitor for mucositis weekly and if ≥ Grade 2 mucositis is observed, omit and/or reduce the dose as outlined in Section 2.2 Table 1 . Administer vitamin B 12 and instruct patients to take folic acid to reduce the risk of mucositis [ see Dosage and Administration ( 2.1 , 2.2 ) and Adverse Reactions ( 6.1 ) ]. 5.3 Dermatologic Reactions FOLOTYN can cause severe dermatologic reactions, which may result in death. These dermatologic reactions have been reported in clinical studies (14/663 patients [2.1%]) and post marketing experience, and have included skin exfoliation, ulceration, and toxic epidermal necrolysis (TEN). They may be progressive and increase in severity with further treatment, and may involve skin and subcutaneous sites of known lymphoma. Monitor patients with dermatologic reactions closely, and if severe, withhold or discontinue FOLOTYN [ see Adverse Reactions ( 6.2 ) and Use in Specific Populations ( 8.7 ) ]. 5.4 Tumor Lysis Syndrome FOLOTYN can cause tumor lysis syndrome (TLS). Monitor patients who are at increased risk of TLS and treat promptly. 5.5 Hepatic Toxicity FOLOTYN can cause hepatic toxicity and liver function test abnormalities. Persistent liver function test abnormalities may be indicators of hepatic toxicity and require dose modification or discontinuation. Monitor liver function tests. Omit dose until recovery, adjust or discontinue therapy based on the severity of the hepatic toxicity [ see Dosage and Administration ( 2.2 ) and Use in Specific Populations ( 8.6 ) ]. 5.6 Risk of Increased Toxicity in the Presence of Impaired Renal Function Patients with moderate to severe renal function impairment may be at greater risk for increased exposure and toxicity. Monitor patients for renal function and systemic toxicity and adjust dosing accordingly. Serious adverse drug reactions including toxic epidermal necrolysis and mucositis were reported in patients with end stage renal disease (ESRD) undergoing dialysis who were administered FOLOTYN therapy. Avoid FOLOTYN use in patients with end stage renal disease including those undergoing dialysis unless the potential benefit justifies the potential risk [ see Dosage and Administration ( 2.2 ), Adverse Reactions ( 6.2 ), Use in Specific Populations ( 8.7 ), and Clinical Pharmacology ( 12.3 ) ]. 5.7 Embryo-Fetal Toxicity FOLOTYN can cause fetal harm when administered to a pregnant woman. FOLOTYN was embryotoxic and fetotoxic in rats and rabbits. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus [ see Use in Specific Populations ( 8.1 ) ].
Adverse reactions cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
adverse reactions
6 ADVERSE REACTIONS The following serious adverse reactions are described below and elsewhere in the labeling: • Bone Marrow Suppression [see Warnings and Precautions ( 5.1 )] • Mucositis [see Warnings and Precautions ( 5.2 )] • Dermatologic Reactions [see Warnings and Precautions ( 5.3 )] • Tumor Lysis Syndrome [see Warnings and Precautions ( 5.4 )] • Hepatic Toxicity [see Warnings and Precautions ( 5.5 )] The most common adverse reactions observed in patients with peripheral T-cell lymphoma (PTCL) treated with FOLOTYN were mucositis, thrombocytopenia, nausea, and fatigue. Most common adverse reactions (>35%) are mucositis, thrombocytopenia, nausea, and fatigue. Most common serious adverse reactions are pyrexia, mucositis, sepsis, febrile neutropenia, dehydration, dyspnea, and thrombocytopenia. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Allos Therapeutics, Inc at 1-888-ALLOS88 (1-888-255-6788) or www.FOLOTYN.com or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch 6.1 Clinical Trials Experience Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in practice. The safety of FOLOTYN was evaluated in 111 PTCL patients in a single-arm clinical study in which patients received a starting dose of 30 mg/m 2 once weekly for 6 weeks in 7-week cycles. The median duration of treatment was 70 days (range 1-540 days). Most Frequent Adverse Reactions Table 4 summarizes the most frequent adverse reactions, regardless of causality, using the National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI CTCAE, version 3.0). Table 4 Adverse Reactions Occurring in PTCL Patients (Incidence ≥ 10% of patients) N=111 Total Grade 3 Grade 4 Preferred Term N % N % N % Any Adverse Event 111 100 48 43 34 31 Mucositis a 78 70 19 17 4 4 Thrombocytopenia b 45 41 15 14 21 19 b Nausea 44 40 4 4 0 0 Fatigue 40 36 5 5 2 2 Anemia 38 34 17 15 2 2 Constipation 37 33 0 0 0 0 Pyrexia 36 32 1 1 1 1 Edema 33 30 1 1 0 0 Cough 31 28 1 1 0 0 Epistaxis 29 26 0 0 0 0 Vomiting 28 25 2 2 0 0 Neutropenia 27 24 14 13 8 7 Diarrhea 23 21 2 2 0 0 Dyspnea 21 19 8 7 0 0 Anorexia 17 15 3 3 0 0 Hypokalemia 17 15 4 4 1 1 Rash 17 15 0 0 0 0 Pruritus 16 14 2 2 0 0 Pharyngolaryngeal pain 15 14 1 1 0 0 Liver function test abnormal c 14 13 6 5 0 0 Abdominal pain 13 12 4 4 0 0 Pain in extremity 13 12 0 0 0 0 Back pain 12 11 3 3 0 0 Leukopenia 12 11 3 3 4 4 Night sweats 12 11 0 0 0 0 Asthenia 11 10 1 1 0 0 Tachycardia 11 10 0 0 0 0 Upper respiratory tract infection 11 10 1 1 0 0 c Alanine aminotransferase, aspartate aminotransferase, and transaminases increased Serious Adverse Events Forty-four percent of patients (n = 49) experienced a serious adverse event while on study or within 30 days after their last dose of FOLOTYN. The most common serious adverse events (> 3%), regardless of causality, were pyrexia, mucositis, sepsis, febrile neutropenia, dehydration, dyspnea, and thrombocytopenia. One death from cardiopulmonary arrest in a patient with mucositis and febrile neutropenia was reported in this trial. Deaths from mucositis, febrile neutropenia, sepsis, and pancytopenia occurred in 1.2% of patients treated on all FOLOTYN trials at doses ranging from 30 to 325 mg/m 2 . Discontinuations Twenty-three percent of patients (n = 25) discontinued treatment with FOLOTYN due to adverse reactions. The adverse reactions reported most frequently as the reason for discontinuation of treatment were mucositis (6%, n = 7) and thrombocytopenia (5%, n = 5). Dose Modifications The target dose of FOLOTYN was 30 mg/m 2 once weekly for 6 weeks in 7-week cycles. The majority of patients (69%, n = 77) remained at the target dose for the duration of treatment. Overall, 85% of scheduled doses were administered. 6.2 Post Marketing Experience Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Dermatologic Reactions Toxic epidermal necrolysis, sometimes fatal, has been reported during post-marketing use of FOLOTYN. Fatal cases have been reported following the first dose of FOLOTYN, including when a reduced dose is given, and have been reported in patients with end-stage renal disease undergoing dialysis [ see Warnings and Precautions ( 5.3 ), Use in Specific Populations ( 8.7 ), and Clinical Pharmacology ( 12.3 ) ].
adverse reactions table
<table cellspacing="0" cellpadding="0" border="0" ID="_Reft4" width="100%"><caption>Table 4 Adverse Reactions Occurring in PTCL Patients (Incidence ≥ 10% of patients) </caption><tbody><tr styleCode="Botrule"><td styleCode="Lrule Rrule" rowspan="2" align="left" valign="top"/><td styleCode="Rrule" colspan="6" align="center" valign="top"><content styleCode="bold"><content styleCode="bold">N=111</content></content> </td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule" colspan="2" align="center" valign="top"><content styleCode="bold"><content styleCode="bold">Total</content></content> </td><td styleCode="Rrule" colspan="2" align="center" valign="top"><content styleCode="bold"><content styleCode="bold">Grade 3</content></content> </td><td styleCode="Rrule" colspan="2" align="center" valign="top"><content styleCode="bold"><content styleCode="bold">Grade 4</content></content> </td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule" align="left" valign="top"><content styleCode="bold"><content styleCode="bold">Preferred Term</content></content></td><td styleCode="Rrule" align="center" valign="top"><content styleCode="bold"><content styleCode="bold">N</content></content> </td><td styleCode="Rrule" align="center" valign="top"><content styleCode="bold"><content styleCode="bold">%</content></content> </td><td styleCode="Rrule" align="center" valign="top"><content styleCode="bold"><content styleCode="bold">N</content></content> </td><td styleCode="Rrule" align="center" valign="top"><content styleCode="bold"><content styleCode="bold">%</content></content> </td><td styleCode="Rrule" align="center" valign="top"><content styleCode="bold"><content styleCode="bold">N</content></content> </td><td styleCode="Rrule" align="center" valign="top"><content styleCode="bold"><content styleCode="bold">%</content></content> </td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule" valign="top">Any Adverse Event </td><td styleCode="Rrule" align="center" valign="top">111 </td><td styleCode="Rrule" align="center" valign="top">100 </td><td styleCode="Rrule" align="center" valign="top">48 </td><td styleCode="Rrule" align="center" valign="top">43 </td><td styleCode="Rrule" align="center" valign="top">34 </td><td styleCode="Rrule" align="center" valign="top">31 </td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule" valign="top"> Mucositis<sup>a</sup> </td><td styleCode="Rrule" align="center" valign="top">78 </td><td styleCode="Rrule" align="center" valign="top">70 </td><td styleCode="Rrule" align="center" valign="top">19 </td><td styleCode="Rrule" align="center" valign="top">17 </td><td styleCode="Rrule" align="center" valign="top">4 </td><td styleCode="Rrule" align="center" valign="top">4 </td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule" valign="top"> Thrombocytopenia<sup>b</sup> </td><td styleCode="Rrule" align="center" valign="top">45 </td><td styleCode="Rrule" align="center" valign="top">41 </td><td styleCode="Rrule" align="center" valign="top">15 </td><td styleCode="Rrule" align="center" valign="top">14 </td><td styleCode="Rrule" align="center" valign="top">21 </td><td styleCode="Rrule" align="center" valign="top">19<sup>b</sup> </td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule" valign="top"> Nausea </td><td styleCode="Rrule" align="center" valign="top">44 </td><td styleCode="Rrule" align="center" valign="top">40 </td><td styleCode="Rrule" align="center" valign="top">4 </td><td styleCode="Rrule" align="center" valign="top">4 </td><td styleCode="Rrule" align="center" valign="top">0 </td><td styleCode="Rrule" align="center" valign="top">0 </td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule" valign="top"> Fatigue </td><td styleCode="Rrule" align="center" valign="top">40 </td><td styleCode="Rrule" align="center" valign="top">36 </td><td styleCode="Rrule" align="center" valign="top">5 </td><td styleCode="Rrule" align="center" valign="top">5 </td><td styleCode="Rrule" align="center" valign="top">2 </td><td styleCode="Rrule" align="center" valign="top">2 </td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule" valign="top"> Anemia </td><td styleCode="Rrule" align="center" valign="top">38 </td><td styleCode="Rrule" align="center" valign="top">34 </td><td styleCode="Rrule" align="center" valign="top">17 </td><td styleCode="Rrule" align="center" valign="top">15 </td><td styleCode="Rrule" align="center" valign="top">2 </td><td styleCode="Rrule" align="center" valign="top">2 </td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule" valign="top"> Constipation </td><td styleCode="Rrule" align="center" valign="top">37 </td><td styleCode="Rrule" align="center" valign="top">33 </td><td styleCode="Rrule" align="center" valign="top">0 </td><td styleCode="Rrule" align="center" valign="top">0 </td><td styleCode="Rrule" align="center" valign="top">0 </td><td styleCode="Rrule" align="center" valign="top">0 </td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule" valign="top"> Pyrexia </td><td styleCode="Rrule" align="center" valign="top">36 </td><td styleCode="Rrule" align="center" valign="top">32 </td><td styleCode="Rrule" align="center" valign="top">1 </td><td styleCode="Rrule" align="center" valign="top">1 </td><td styleCode="Rrule" align="center" valign="top">1 </td><td styleCode="Rrule" align="center" valign="top">1 </td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule" valign="top"> Edema </td><td styleCode="Rrule" align="center" valign="top">33 </td><td styleCode="Rrule" align="center" valign="top">30 </td><td styleCode="Rrule" align="center" valign="top">1 </td><td styleCode="Rrule" align="center" valign="top">1 </td><td styleCode="Rrule" align="center" valign="top">0 </td><td styleCode="Rrule" align="center" valign="top">0 </td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule" valign="top"> Cough </td><td styleCode="Rrule" align="center" valign="top">31 </td><td styleCode="Rrule" align="center" valign="top">28 </td><td styleCode="Rrule" align="center" valign="top">1 </td><td styleCode="Rrule" align="center" valign="top">1 </td><td styleCode="Rrule" align="center" valign="top">0 </td><td styleCode="Rrule" align="center" valign="top">0 </td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule" valign="top"> Epistaxis </td><td styleCode="Rrule" align="center" valign="top">29 </td><td styleCode="Rrule" align="center" valign="top">26 </td><td styleCode="Rrule" align="center" valign="top">0 </td><td styleCode="Rrule" align="center" valign="top">0 </td><td styleCode="Rrule" align="center" valign="top">0 </td><td styleCode="Rrule" align="center" valign="top">0 </td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule" valign="top"> Vomiting </td><td styleCode="Rrule" align="center" valign="top">28 </td><td styleCode="Rrule" align="center" valign="top">25 </td><td styleCode="Rrule" align="center" valign="top">2 </td><td styleCode="Rrule" align="center" valign="top">2 </td><td styleCode="Rrule" align="center" valign="top">0 </td><td styleCode="Rrule" align="center" valign="top">0 </td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule" valign="top"> Neutropenia </td><td styleCode="Rrule" align="center" valign="top">27 </td><td styleCode="Rrule" align="center" valign="top">24 </td><td styleCode="Rrule" align="center" valign="top">14 </td><td styleCode="Rrule" align="center" valign="top">13 </td><td styleCode="Rrule" align="center" valign="top">8 </td><td styleCode="Rrule" align="center" valign="top">7 </td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule" valign="top"> Diarrhea </td><td styleCode="Rrule" align="center" valign="top">23 </td><td styleCode="Rrule" align="center" valign="top">21 </td><td styleCode="Rrule" align="center" valign="top">2 </td><td styleCode="Rrule" align="center" valign="top">2 </td><td styleCode="Rrule" align="center" valign="top">0 </td><td styleCode="Rrule" align="center" valign="top">0 </td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule" valign="top"> Dyspnea </td><td styleCode="Rrule" align="center" valign="top">21 </td><td styleCode="Rrule" align="center" valign="top">19 </td><td styleCode="Rrule" align="center" valign="top">8 </td><td styleCode="Rrule" align="center" valign="top">7 </td><td styleCode="Rrule" align="center" valign="top">0 </td><td styleCode="Rrule" align="center" valign="top">0 </td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule" valign="top"> Anorexia </td><td styleCode="Rrule" align="center" valign="top">17 </td><td styleCode="Rrule" align="center" valign="top">15 </td><td styleCode="Rrule" align="center" valign="top">3 </td><td styleCode="Rrule" align="center" valign="top">3 </td><td styleCode="Rrule" align="center" valign="top">0 </td><td styleCode="Rrule" align="center" valign="top">0 </td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule" valign="top"> Hypokalemia </td><td styleCode="Rrule" align="center" valign="top">17 </td><td styleCode="Rrule" align="center" valign="top">15 </td><td styleCode="Rrule" align="center" valign="top">4 </td><td styleCode="Rrule" align="center" valign="top">4 </td><td styleCode="Rrule" align="center" valign="top">1 </td><td styleCode="Rrule" align="center" valign="top">1 </td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule" valign="top"> Rash </td><td styleCode="Rrule" align="center" valign="top">17 </td><td styleCode="Rrule" align="center" valign="top">15 </td><td styleCode="Rrule" align="center" valign="top">0 </td><td styleCode="Rrule" align="center" valign="top">0 </td><td styleCode="Rrule" align="center" valign="top">0 </td><td styleCode="Rrule" align="center" valign="top">0 </td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule" valign="top"> Pruritus </td><td styleCode="Rrule" align="center" valign="top">16 </td><td styleCode="Rrule" align="center" valign="top">14 </td><td styleCode="Rrule" align="center" valign="top">2 </td><td styleCode="Rrule" align="center" valign="top">2 </td><td styleCode="Rrule" align="center" valign="top">0 </td><td styleCode="Rrule" align="center" valign="top">0 </td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule" valign="top"> Pharyngolaryngeal pain </td><td styleCode="Rrule" align="center" valign="top">15 </td><td styleCode="Rrule" align="center" valign="top">14 </td><td styleCode="Rrule" align="center" valign="top">1 </td><td styleCode="Rrule" align="center" valign="top">1 </td><td styleCode="Rrule" align="center" valign="top">0 </td><td styleCode="Rrule" align="center" valign="top">0 </td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule" valign="top"> Liver function test abnormal<sup>c</sup> </td><td styleCode="Rrule" align="center" valign="top">14 </td><td styleCode="Rrule" align="center" valign="top">13 </td><td styleCode="Rrule" align="center" valign="top">6 </td><td styleCode="Rrule" align="center" valign="top">5 </td><td styleCode="Rrule" align="center" valign="top">0 </td><td styleCode="Rrule" align="center" valign="top">0 </td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule" valign="top"> Abdominal pain </td><td styleCode="Rrule" align="center" valign="top">13 </td><td styleCode="Rrule" align="center" valign="top">12 </td><td styleCode="Rrule" align="center" valign="top">4 </td><td styleCode="Rrule" align="center" valign="top">4 </td><td styleCode="Rrule" align="center" valign="top">0 </td><td styleCode="Rrule" align="center" valign="top">0 </td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule" valign="top"> Pain in extremity </td><td styleCode="Rrule" align="center" valign="top">13 </td><td styleCode="Rrule" align="center" valign="top">12 </td><td styleCode="Rrule" align="center" valign="top">0 </td><td styleCode="Rrule" align="center" valign="top">0 </td><td styleCode="Rrule" align="center" valign="top">0 </td><td styleCode="Rrule" align="center" valign="top">0 </td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule" valign="top"> Back pain </td><td styleCode="Rrule" align="center" valign="top">12 </td><td styleCode="Rrule" align="center" valign="top">11 </td><td styleCode="Rrule" align="center" valign="top">3 </td><td styleCode="Rrule" align="center" valign="top">3 </td><td styleCode="Rrule" align="center" valign="top">0 </td><td styleCode="Rrule" align="center" valign="top">0 </td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule" valign="top"> Leukopenia </td><td styleCode="Rrule" align="center" valign="top">12 </td><td styleCode="Rrule" align="center" valign="top">11 </td><td styleCode="Rrule" align="center" valign="top">3 </td><td styleCode="Rrule" align="center" valign="top">3 </td><td styleCode="Rrule" align="center" valign="top">4 </td><td styleCode="Rrule" align="center" valign="top">4 </td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule" valign="top"> Night sweats </td><td styleCode="Rrule" align="center" valign="top">12 </td><td styleCode="Rrule" align="center" valign="top">11 </td><td styleCode="Rrule" align="center" valign="top">0 </td><td styleCode="Rrule" align="center" valign="top">0 </td><td styleCode="Rrule" align="center" valign="top">0 </td><td styleCode="Rrule" align="center" valign="top">0 </td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule" valign="top"> Asthenia </td><td styleCode="Rrule" align="center" valign="top">11 </td><td styleCode="Rrule" align="center" valign="top">10 </td><td styleCode="Rrule" align="center" valign="top">1 </td><td styleCode="Rrule" align="center" valign="top">1 </td><td styleCode="Rrule" align="center" valign="top">0 </td><td styleCode="Rrule" align="center" valign="top">0 </td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule" valign="top"> Tachycardia </td><td styleCode="Rrule" align="center" valign="top">11 </td><td styleCode="Rrule" align="center" valign="top">10 </td><td styleCode="Rrule" align="center" valign="top">0 </td><td styleCode="Rrule" align="center" valign="top">0 </td><td styleCode="Rrule" align="center" valign="top">0 </td><td styleCode="Rrule" align="center" valign="top">0 </td></tr><tr><td styleCode="Lrule Rrule" valign="top"> Upper respiratory tract infection </td><td styleCode="Rrule" align="center" valign="top">11 </td><td styleCode="Rrule" align="center" valign="top">10 </td><td styleCode="Rrule" align="center" valign="top">1 </td><td styleCode="Rrule" align="center" valign="top">1 </td><td styleCode="Rrule" align="center" valign="top">0 </td><td styleCode="Rrule" align="center" valign="top">0 </td></tr></tbody></table>
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.